GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00742261
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2017-07-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT00742131
A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure
- Conditions
- Heart Failure, Congestive
- Interventions
- Drug: SK&F-105517-D 10 mg capsuleDrug: Carvedilol-immediate release (IR) 2.5 mg tabletDrug: Carvedilol-IR 10 mg tabletDrug: SK&F-105517-D 20 mg capsuleDrug: SK&F-105517-D 40 mg capsule
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT00742508
- Locations
- 🇯🇵
GSK Investigational Site, Wakayama, Japan
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT00742144
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT00733551
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00733980
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
- Conditions
- Atherosclerosis
- Interventions
- Drug: SB480848 Placebo TabletDrug: SB480848 40mg EC TabletDrug: SB480848 80mg EC TabletDrug: SB480848 160mg EC Tablet
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 107
- Registration Number
- NCT00734032
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00733577
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
An Extension to Study MD7108240
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT00733304
- Locations
- 🇮🇹
GSK Investigational Site, Padova, Veneto, Italy
PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00733785
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany